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INTRODUCTION
With greater industrialization, people have shown stronger 
preferences for Western-style diets of high fat content than 
traditional diets. This change in dietary preferences has con-
tributed to a dramatic increase in metabolic diseases, such as 
obesity and type 2 diabetes, over the last decade, and these 
diseases now are a significant threat to the public health.1 In 
obesity and type 2 diabetes, inflammatory cells infiltrate adi-
pose tissues, the liver, and pancreatic islets leading to the pro-
duction of proinflammatory cytokines and chemokines; these 
metabolic diseases are now considered as chronic low-grade 
inflammatory diseases. Metabolic inflammation consequent-
ly causes insulin resistance, contributing to the development 
of metabolic syndrome.2 However, the underlying mechanisms 
of low-grade tissue inflammation inducing metabolic symp-
toms have still not been clearly elucidated. Recently, a modest 
increase in plasma contents of lipopolysaccharide (LPS) has 
been incriminated as an etiological event causing metabolic 
inflammation. The gut microbiota are a strong candidate as 
sources of the noted increases in plasma LPS.3 In this regard, 
gut microbiota seem to influence systemic immunity and lo-
cal intestinal immunity. Moreover, gut microbiota are changed 
by obesity, which is followed by the altered intestinal immu-
nity, contributing substantially to the pathogenesis of metabol-
ic diseases. In this review, we summarize recent findings on 
changes in gut microbiota and intestinal immunity in associa-
tion with diet-induced obesity and insulin resistance. 
CHANGES IN GUT MICROBIOTA  
ASSOCIATED WITH METABOLIC  
SYNDROME
How does intestinal microbiota influence obesity and 
diabetes?
The gut microbiota in humans consist of 10−100 trillion micro-
organisms and outnumber all somatic and germ cells by 10,4 
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Gut microbiota play critical physiological roles in energy extraction from the intestine and in the control of systemic immunity, as 
well as local intestinal immunity. Disturbance of gut microbiota leads to the development of several diseases, such as colitis, in-
flammatory bowel diseases, metabolic disorders, cancer, etc. From a metabolic point of view, the gut is a large metabolic organ and 
one of the first to come into contact with dietary fats. Interestingly, excessive dietary fat has been incriminated as a primary cul-
prit of metabolic syndrome and obesity. After intake of high-fat diet or Western diet, extensive changes in gut microbiota have been 
observed, which may be an underlying cause of alterations in whole body metabolism and nutrient homeostasis. Here, we sum-
marize recent data on changes in the gut microbiota and immunity associated with dietary fat, as well as their relationships with 
the pathogenesis of metabolic syndrome. These findings may provide insight into the understanding of the complex pathophysiolo-
gy related to the development of metabolic diseases and offer an opportunity to develop novel candidates for therapeutic agents.
Key Words: Gut microbiota, gut immunity, obesity, diabetes
Review Article 
pISSN: 0513-5796 · eISSN: 1976-2437
Yonsei Med J 2017 Nov;58(6):1083-1091
https://doi.org/10.3349/ymj.2017.58.6.1083
1084
Gut Microbiota and Host Metabolism
https://doi.org/10.3349/ymj.2017.58.6.1083
although it has recently been claimed that such number could 
be an overestimation. Further, the collective genomes of the 
gut microbiome contain 100-fold more genes than our own 
genome.5 Gut microbiota have coevolved with humans, elicit-
ing profound effects on various physiological processes, such 
as nutrient metabolism and immunity. For instance, dietary 
fibers that the human host cannot digest are metabolized by gut 
microbiota into short-chain fatty acids (SCFAs), such as butyr-
ate, acetate, and propionate. SCFAs act through G protein-cou-
pled receptors GPR41 and GPR43 expressed in enteroendo-
crine cells, enteric neurons, and enteric leukocytes.6 Butyrate 
and propionate activate intestinal gluconeogenesis and exert 
beneficial effects on glucose and energy homeostasis: butyr-
ate activates gluconeogenesis gene expression in a cAMP-de-
pendent manner, whereas propionate does it through gut-brain 
neural circuits.7 Intestinal gluconeogenesis elicits beneficial 
effects on systemic glucose profiles through portal vein glucose 
sensors transmitting the signal to the brain.8 Butyrate also en-
hances gut barrier function and can protect enterocytes from 
injury or colitis,9 which might be related to the role of butyrate 
as a histone deacetylator inhibitor.10,11 On the immunological 
aspect, butyrate can promote Treg cell generation in the intes-
tine.12 Acetate has anti-inflammatory activity against colitis and 
arthritis.13 Meanwhile, however, acetate may also increase glu-
cose-stimulated insulin secretion and ghrelin secretion via 
parasympathetic activation, leading to increased food intake 
and obesity.14 In addition to these effects, SCFAs can contribute 
to improvement of metabolic syndrome by promoting secre-
tions of peptide hormones, such as peptide YY and glucagon-
like peptide-1, that decrease appetite and increase insulin re-
lease, respectively (Fig. 1).15 
Recently, many studies have shown that change in the gut 
microbiota is related to the development of obesity and diabe-
tes: germ-free (GF) mice are resistant to high-fat diet (HFD)-in-
duced obesity and glucose intolerance due to de-repressed ex-
pression of fasting-induced adipose factor (Fiaf) in the intestinal 
epithelium.16,17 Fiaf, which prevents fat storage in adipocytes via 
inhibition of lipoprotein lipase and is also called angiopoietin-
like protein 4 (Angptl4), is suppressed by gut microbiota. In-
terestingly, transfer of gut microbiota from obese mice to re-
cipient GF mice significantly increased body fat content and 
insulin resistance, compared to the transfer of gut microbiota 
from lean mice.18,19 These results suggest a crucial role of gut 
microbiota in nutrient homeostasis and also a possible etiologi-
cal role of altered gut microbiota in the development of meta-
bolic syndrome. 
Phylum level changes and enterotype 
To investigate the role of microbiota in nutrient uptake or in the 
development of metabolic syndrome, identification of indi-
vidual microorganism is crucial. However, identification of gut 
microbiota has been extremely difficult since they are largely 
recalcitrant to in vitro culture. This technical obstacle can now 
be overcome with the advent of a revolutionary method of mi-
croorganism identification, sequencing of 16s rRNA genes that 
are ubiquitous and highly conserved among microorganisms.20 
Combined with next-generation sequencing technology, 16s 
rRNA gene sequencing allows the identification of enormous 
complexity of enteric bacteria. 
In the intestines of mouse and humans, >90% of bacterial 
species are composed of Bacteroidetes and Firmicutes phyla, 
while Actinobacteria, Proteobacteria, and Verrucomicrobia con-
stitute relatively minor proportions. Compared with their lean 
counterparts, leptin-deficient ob/ob mice have a decreased 
abundance of Bacteroidetes and a correspondingly increased 
abundance of Firmicutes.21 Further studies have confirmed 
similar changes in mice with diet-induced obesity, a more 
physiological model of obesity than ob/ob mice, while overall 
diversity among Firmicutes is different from that of ob/ob 
mice.18 Similar changes in gut microbiota have also been ob-
served in humans.19 Furthermore, there seems to be a causality 
between changes in gut microbiota and obesity, since transfer 
of gut microbiota from obese mice to recipient GF mice pro-
motes fat deposition.18 The mechanism of increased Firmicutes 
abundance in obesity might be related to an enrichment of ho-
moacetogens belonging to Firmicutes in obesity, which facili-
tates disposal of H2 produced by anaerobic bacteria during fer-
mentation of nutrients.22 Among Bacteroidetes, a role for 
Bacteroides thetaiotaomicron, a glutamate-fermenting bacteria, 
in obesity was addressed in a recent study. Administration of 
Bacteroides thetaiotaomicron, the abundance of which was re-
duced in mice fed HFD, lowered fat mass and metabolic in-
flammation, which was associated decreased serum concen-
trations of glutamate and branched-chain amino acids.23 
Although it has been generally accepted that the abundance 
of Bacteroidetes is decreased and that of Firmicutes are in-
creased in obesity, it does not necessarily mean that the abun-
dances of all bacteria belonging to Firmicutes phylum increase 
and those of all bacteria belonging to Bacteroidetes phylum de-
crease. Instead, at the genus level, the abundance of Gram-pos-
itive Lactobacillus belonging to Firmicutes phylum decreases 
and the abundances of Gram-negative Bacteroides and Pre-
votella belonging to Bacteroidetes phylum increase.24 Given that 
a major component of the outer membrane of Gram-negative 
bacteria is endotoxin or LPS, an increased abundance of Gram-
negative Bacteroides and Prevotella may be linked to endotox-
emia-induced metabolic inflammation. 
It has also been reported that patients with diabetes have a 
reduced abundance of butyrate-producing Clostridiales be-
longing to Firmicutes (Roseburia and Faecalibacterium prauznit-
zii) and an increased abundance of non-butyrate-producing 
Clostridiales, suggesting differential regulation of the same 
Clostridiales, depending on the production of SCFAs.25,26 Fae-
calibacterium prauznitzii produces not only butyrate but also 
microbial anti-inflammatory molecules that can affect gut in-
flammation.27 Besides microbiota belonging to Bacteroidetes 
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and Firmicutes phyla, abundance of Proteobacteria phylum 
has also been reported to be increased by HFD.28 Since Pro-
teobacteria are Gram-negative bacteria, their increase may be 
related to endotoxemia-induced metabolic inflammation. 
Gut microbiota is also important in the digestion of dietary 
fiber, which can modulate diverse aspects of gut immunity 
and metabolism. Dietary fiber-induced improvement of glu-
cose profiles has been shown to be associated with an increased 
abundance of Prevotella species, such as P. copri, a Gram-
negative bacteria belonging to Bacteroidetes phylum.29 Indeed, 
Prevotella has been reported to reflect long-term intake of 
carbohydrates, while Bacteroides reflects that of animal fat, 
among three bacteria characterizing enterotypes (Prevotella, 
Bacteroides, and Ruminococcus).30
These changes in microbiota composition in obesity may 
be able to work as early diagnostic markers in the clinic to bet-
ter identify obese subjects who are prone to develop diabetes, 
and could be also novel therapeutic targets in the manage-
Fig. 1. Regulation of host metabolism and immunity by gut microbiota. Under a fiber-rich diet, gut microbiota metabolize undigested dietary fiber into 
SCFAs (acetate, propionate, and butyrate), affecting host metabolism and immunity. Microbial metabolites from this process improve host metabo-
lism. In particular, the secretion of peptide hormones, such as PYY and GLP-1, is promoted by microbial metabolites: PYY decreases appetite and 
GLP-1 lowers blood glucose level via promotion of insulin secretion. Among SCFAs, butyrate and propionate activate intestinal gluconeogenesis and 
improve systemic glucose profiles. Meanwhile, acetate promotes secretion of ghrelin, a hunger hormone, and increases food intake, consequently 
causing hyperphagia and obesity. Nevertheless, acetate has anti-inflammatory function like butyrate. Butyrate enhances gut barrier function of intes-
tinal epithelial cells and increases regulatory T (Treg) cells. In addition, gut microbiota suppress expression of fasting-induced adipose factor (Fiaf), 
an inhibitor of LPL, promoting fat storage in adipocytes. Under fiber-deficient diet, mucus-degrading bacteria expand and impair the integrity of the 
mucus layer. Thereby, endotoxemia-induced metabolic inflammation ensues. SCFAs, short-chain fatty acids; PYY, peptide YY; GLP-1, glucagon-like 
peptide-1; LPL, lipoprotein lipase.
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ment of obesity or diabetes.
Changes in Akkermansia in metabolic syndrome
One of the prominent changes in gut microbiota associated 
with metabolic syndrome is that of Akkermansia muciniphila. 
Akkermansia muciniphila has recently been identified as a 
Gram-negative bacteria with mucolytic activity and the most 
abundant species of the Verrucomicrobia phylum. An abun-
dance of Akkermansia muciniphila has been shown to be in-
versely correlated with body weight and reduced by HFD.31,32 
Fish oil consumption has been found to increase the abun-
dance of Akkermansia, which is associated with metabolic 
improvement.33 These results suggest that decreased abun-
dance of Akkermansia may contribute to the metabolic dete-
riorations associated with HFD. Nevertheless, there is also a 
report that an abundance of Akkermansia increases in patients 
with diabetes,26 which might be related to patient selection, 
such as inclusion of patients under treatment with antidiabet-
ic medicines affecting gut microbiota. Changes in Akkerman-
sia abundance associated with HFD are opposite those in Bi-
lophila wadsworthia,34 which is increased by milk-derived 
saturated fat and can aggravate colitis.35 The abundance of Ak-
kermansia is decreased in older adults, although the signifi-
cance of this finding is unclear.36 
   The in vivo effect of Akkermansia on systemic metabolism 
was demonstrated by oral administration of Akkermansia to 
mice with diet-induced obesity. Akkermansia administration 
improves glucose profiles and insulin sensitivity.37,38 Although 
the underlying mechanisms of the beneficial metabolic effects 
of Akkermansia are unclear, Akkermansia seems to decrease 
metabolic inflammation through Treg cell induction in adipose 
tissue.34,38 In addition to the indirect effect of Akkermansia on 
systemic metabolism through regulation of the immune sys-
tem, Akkermansia may directly affect metabolic processes. The 
abundance of Akkermansia is reduced after prolonged cold 
exposure. Furthermore, adaptive changes maximizing caloric 
uptake, such as increased intestinal villi length during cold ex-
posure, are attenuated by Akkermansia transfer, suggesting 
negative energy balance by Akkermansia.39 Akkermansia abun-
dance is also correlated with the gene expression of fatty acid 
oxidation and fat browning.34 
   The beneficial metabolic effect of Akkermansia was also dem-
onstrated in other experimental systems. For instance, the 
abundance of Akkermansia is increased in animals with gas-
tric bypass showing reduced body weight, and is positively cor-
related with metabolic improvement after calorie restriction 
in experimental animals.40,41 Additionally, Akkermansia has a 
protective effect against the development of atherosclerosis.42 
   The metabolic action of metformin, the first-line anti-diabetic 
therapy recommended by the American Diabetes Association 
and the European Association for the Study of Diabetes, also 
appears to be related to changes in gut microbiota. Metformin 
administration increases the abundance of Akkermansia, which 
is accompanied by an increase in mucin-producing goblet 
cells. Moreover, administration of metformin ameliorates met-
abolic inflammation and restores Treg cells in adipose tissue, 
similar to the effect of Akkermansia administration.38,43 In a pre-
vious study, metformin action on gut microbiota of HFD-fed 
mice is analogous to the metformin action on gut microbiota 
of Caenorhabditis elegans, which results in alteration of folate 
and the methionine metabolism of E. coli in the intestine of 
the worm.44 Intriguingly, metformin administration greatly in-
creases the abundance of Akkermansia in patients with type 2 
diabetes as well.45,46 
   While these results suggest potential therapeutic value of Ak-
kermansia or its components as a drug candidate against meta-
bolic syndrome, such prospects have been hampered by the 
sensitivity of Akkermansia to oxygen, the presence of animal-
derived compounds in its growth medium, and the absence of 
metabolic effects of killed bacteria.37,38 However, a recent pa-
per showed that Akkermansia can be cultured successfully in 
a synthetic medium, which contains no compounds that are 
incompatible with human administration, and also that the 
pasteurized Akkermansia has stronger effects than live bacteri-
um. Furthermore, Amun_1100, active component of Akkerman-
sia that is resistant to pasteurization was identified, brighten-
ing the prospect for the development of novel therapeutics 
against metabolic syndrome and diabetes.47
  
 
CHANGES IN INNATE IMMUNITY OF THE 
INTESTINE IN METABOLIC SYNDROME
Role of gut innate immune receptors in metabolic 
syndrome
Several recent studies have suggested that disruption of the 
gut barrier function and the gut microbiota-derived LPS could 
contribute to the pathogenesis of metabolic syndrome and di-
abetes. HFD increases gut permeability and reduces the ex-
pression of tight junction proteins, such as occludin, in gut epi-
thelium.48 Gut barrier disruption in HFD-fed mice increases 
gut permeability, resulting in the passage of LPS into the sys-
temic circulation and low-grade metabolic inflammation.3,24 
Consistent with these data, toll-like receptor 4 (TLR4)-knockout 
mice are resistant to diet-induced insulin resistance.49 NACHT, 
LRR, and PYD domains-containing protein 3 (NLRP3), a mem-
ber of the Nod-like receptor (NLR) family, plays a crucial role 
in inflammasome activation and metabolic inflammation as-
sociated with metabolic syndrome and diabetes.50,51 Increased 
systemic LPS due to disrupted gut barrier function can activate 
not only TLR4 but also NLRP3, together with palmitic acid or 
other inflammasome activators that can be increased in obesity 
or metabolic syndrome.51 However, it is not clear whether such 
metabolic inflammation is associated with changes of innate 
immune system in the intestine. Since several TLRs and NLRs 
are expressed in diverse cells of the intestine,52,53 it is likely that 
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these innate immune receptors in the intestine contribute to 
the development of metabolic syndrome. A direct role of intes-
tinal TLR in metabolic syndrome has been demonstrated us-
ing mice with targeted disruption of MyD88, specifically in gut 
epithelial cells that are partially protected from diet-induced 
obesity and metabolic inflammation.54 In contrast, MyD88 de-
letion in myeloid cells does not improve the metabolic profile 
of mice fed HFD, indicating a more important role of innate 
immune receptors in intestinal epithelial cells than in myeloid 
cells in the development of metabolic syndrome.  
   An intriguing model of metabolic syndrome associated with 
the activation of innate immune receptors in the intestine is the 
occurrence of metabolic syndrome in TLR5-knockout mice. 
The development of metabolic syndrome in TLR5-knockout 
mice appears to be due to changes in gut microbiota associated 
with the absence of TLR5 in the intestine, since fecal microbi-
al transplantation confers transfer of metabolic phenotype to 
wild-type mice.55 Following studies showed a crucial role of 
the absence of TLR5 in intestinal epithelial cells, but not that 
in dendritic cells (DCs), in the development of metabolic syn-
drome.56 Altered gut microbiota in TLR5-knockout mice can 
increase hepatic lipogenesis mediated by stearoyl CoA desat-
urase through production of cecal SCFAs.57 
Changes in innate immune cells in the gut of 
metabolic syndrome
At the cell level, several changes were noted in obese subjects 
or HFD-fed mice. Recent investigations revealed a critical role 
of innate lymphoid cells (ILCs) that are derived from common 
lymphoid progenitors, but devoid of antigen receptors, in the 
development of metabolic syndrome. In adipose tissue, group 
2 ILCs (ILC2s) producing Th2 cytokines, such as interleukin 
(IL)-4 and IL-13, play important roles in beige fat biogenesis, 
thermogenesis, and polarization of alternatively activated 
(M2) macrophages, and the proportion of ILC2s is reduced by 
HFD.58,59 In the intestine, NKp46+ group 3 ILCs (ILC3s) mainly 
producing IL-22 are decreased by HFD,60 which could be due 
to reduced expression of IL-23, an upstream regulator of IL-22. 
Since it has been reported that IL-22 improves insulin sensitivi-
ty, preserves intestinal barrier function, decreases chronic in-
flammation, and regulates lipid metabolism in liver and adipose 
tissues,61 NKp46+ ILC3s seem to alleviate metabolic syndrome 
via IL-22 production. 
Macrophages and DCs are crucial members of innate im-
mune cells belonging to antigen-presenting cells (APCs). In 
particular, macrophages and DCs in the intestine can be divid-
ed into several types with distinct functions.62 However, owing 
to the difficulty in preparing immune cells from the intestine 
of HFD-fed mice, there are only few reports studying the ch-
anges of APCs in the intestine of experimental animals with 
metabolic syndrome. One study showed that expressions of 
ICAM1, CD86 costimulatory molecule and certain cytokines 
(IL-6 and IL-12p40) in intestinal APCs are downregulated by 
HFD, which consequently affects intestinal adaptive immuni-
ty.63 Another study showed that intestinal CX3CR1+ macro-
phages can be divided into two subsets with different functions, 
and the frequencies of these two subsets are significantly af-
fected by HFD: the proportion of a CD103–CX3CR1+CD11chigh 
subset increases, whereas that of a CD103–CX3CR1+CD11clow 
subset decreases (Fig. 2).64 In contrast, the proportion of CD103+ 
DCs is not affected by HFD. Given that CD103–CX3CR1+CD11chigh 
macrophages preferentially induce Th1 cells and CD103–
CX3CR1+CD11clow macrophages preferentially induce Th17 
cells, changes in their abundances may be linked to alterna-
tions of intestinal adaptive immunity (see below section regard-
ing adaptive immunity of the gut). 
CHANGES IN THE ADAPTIVE IMMUNITY 
OF THE GUT IN METABOLIC SYNDROME
Recent investigations have shown a significant change in the 
adaptive immunity of the intestine in association with meta-
bolic syndrome: Th1 cell increases and Treg cell decreases in 
the intestinal lamina propria of HFD-fed mice.60 In humans, 
CD8αβ+ intraepithelial lymphocytes (IELs) are increased by 
obesity, and these IELs impair insulin sensitivity of epithelial 
cells.65 In addition to cells traditionally associated with meta-
bolic abnormalities, Th17 cells in the intestine may also play a 
role in the control of metabolic inflammation. According to two 
recent studies, although Th17 cells are well-known potent ef-
fector cells in autoimmune diseases, their reduction in the small 
intestine has been found to contribute to onset of HFD-in-
duced metabolic changes.63 Supporting this contention, sev-
eral studies have shown that Th17 cells do not always induce 
immune/inflammatory disorders and can be divided into pa-
thogenic and non-pathogenic cells.66,67 In this regard, intestinal 
Th17 cells decreased by HFD seem to be non-pathogenic Th17 
cells, rather than pathogen Th17 cells. The loss of Th17 cells in 
the small intestine of HFD-fed mice can be explained by the 
diminished ability of intestinal CX3CR1+ macrophages to in-
duce Th17 cells and a significant reduction of CD103–CX3CR1+ 
CD11clow macrophages, the most efficient Th17-inducing APC 
subset64 (Fig. 2). Transfer of Th17 cells, unlike that of Th1 cells, 
was shown to alleviate weight gain, increased fat mass, and 
glucose intolerance of HFD-fed Rag1-knockout mice. However, 
Th17 cells from integrin β7-knockout mice had no such meta-
bolic effects, suggesting that gut homing of Th17 cells is crucial 
in the metabolic improvement by Th17 cells. LPAM-1 (α4β7) is 
a critical receptor for gut homing of T cells.68,69 In addition, IL-17 
per se plays an important role in the improvement of metabolic 
profiles, since Th17 cells from IL-17-knockout mice have sig-
nificantly less metabolic effects.64 Given that Th17 cells produce 
IL-22, as well as IL-17, Th17 cells may also improve metabolic 
syndrome via IL-22 production.61 Moreover, since Th17 cell tr-
ansfer leads to expansion of microbiota associated with lean 
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phenotype, such as Bacteriodetes or Akkermansia,64 the role of 
gut microbiota cannot be overlooked in regards to the meta-
bolic improvement by Th17 cells. Alteration of gut microbiota 
by Th17 cells may be due to changes in antimicrobial pep-
tides, such as Reg3γ produced by Paneth cells (Fig. 2). In sup-
port of this notion, reduced Paneth cell granules and Reg3γ 
expression in HFD-fed mice are reversed by IL-17 produced by 
Th17 cells.64 IL-17 can also enhance gut barrier function th-
rough upregulation of tight junction molecules, such as clau-
din, in intestinal epithelial cells.70 These data show an intrigu-
ing role of Th17 in metabolic regulation and the potential of gut-
trophic Th17 cell transfer as a new therapy for metabolic syn-
drome or diabetes. 
Fig. 2. Changes in the intestinal immunity by HFD. HFD changes intestinal immunity, as well as gut microbiota composition. HFD, in particular, increas-
es the frequency of Th1 cells among the CD4 T cells and decreases those of Th17 and Treg cells. HFD increases the frequency of a CX3CR1+CD11chigh 
macrophage (MΦ) subset, preferentially inducing Th1 cells, and decreases that of a CX3CR1+CD11clow MΦ subset, preferentially inducing Th17 cells 
without affecting that of CD103+ DCs. Changes in the proportions of two MΦ subsets lead to the changes in Th1 and Th17 cells after HFD feeding. In-
triguingly, intestinal Th17 cells play an important role in improving metabolic diseases through IL-17 and IL-22. IL-22 is produced also by ILC3 and 
functions to improve metabolic profiles. Proportions of ILC3 are decreased by HFD. IL-17, mainly produced by Th17 cells, reverses decreased gran-
ules and antimicrobial peptide production of Paneth cells, leading to expansion of microbiota associated with lean phenotype. In addition, IL-17 en-
hances barrier function of intestinal epithelial cell by increasing expression of tight junction molecules. HFD, high-fat diet; DCs, dendritic cells; IL, in-
terleukin, ILC3, group 3 innate lymphoid cells.
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MODULATION OF GUT MICROBIOTA OR 
IMMUNITY AS A NOVEL THERAPEUTIC 
STRATEGY AGAINST METABOLIC 
SYNBDROME AND DIABETES
Gut microbiota and immunity can be modulated by prebiot-
ics or probiotics. Prebiotics are food components that induce ex-
pansion of beneficial microbiota. For example, oligofructose 
promotes the growth of Bifidobacterium that reduces endotox-
in levels and enhances intestinal barrier function, improving 
metabolic parameters.71 In contrast to lard, fish oil rich in poly-
unsaturated fat promotes growth of beneficial bacteria, such as 
Akkermansia, Bifidobacterium, or Lactobacillus, and prevents 
metabolic inflammation in adipose tissue.33 In addition, a fiber-
rich diet may contribute to amelioration of metabolic syndrome 
by inhibiting expansion and activity of mucus-degrading bac-
teria that are harmful to the intestinal barrier function (Fig. 1).72 
Food enriched with inulin may have protective effects against 
gut injury associated with HFD and diet-induced obesity, since 
deficiency of inulin in HFD has been reported to a vital element 
in the loss of cecal and colonic mass due to HFD.73 
Probiotics are live microorganisms that confer a beneficial 
effect on the host when administered properly. Some probiotic 
strains, especially those of the genera Lactobacillus and Bi-
fiodobacterium, have been reported to ameliorate obesity and 
improve metabolic parameters. The suggested mechanisms 
thereof include inhibition of pathogen adherence to gut epi-
thelium, stabilization of gut microbial community, and protec-
tion of mucosal integrity or barrier function.71,74 Enhanced gut 
barrier function may be due to SCFA production by bacterial 
fermentation. A recent study reported direct beneficial activity 
of Lactobacilli on intestinal epithelial cells and on the enteric 
nervous system regulating gut motility.75
In addition to prebiotics and probiotics, drugs can also be em-
ployed to modulate gut microbiota or immunity. As discussed 
above, the anti-diabetic drug metformin can exert beneficial 
metabolic effects through modulation of gut microbiota in mice 
and human patients.38,43,46 The action of metformin as an anti-
aging or pro-longevity agent38,43 may also be related to its ef-
fect on gut microbiota.44 Anti-inflammatory agent 5-aminosali-
cylic acid can improve metabolic syndrome through suppres-
sion of inflammation as well.60 Active components of Akker-
mansia, such as Amuc_1100, and delivery of gut-tropic Th17 
cells or agents that can boost non-pathogenic Th17 cells, spe-
cifically in the intestine, may also be able to open a new horizon 
in the development of next-generation therapies against met-
abolic syndrome or diabetes. 
CONCLUSION
Changes in the gut microbiota and immunity are being accept-
ed as important elements in the development of metabolic 
syndrome and diabetes. However, still numerous questions 
need to be elucidated to clearly understand the interaction be-
tween microbiota and gut immunity or disturbance therein as-
sociated with the diseases. Future studies addressing the com-
plex interplay between gut microbiota, immunity, and host 
metabolism in a physiological and pathological context will 
pave the way for the development of innovative therapeutic 
agents against metabolic syndrome and diabetes.
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